Preventing the cardiotoxic effects of anthracyclines: From basic concepts to clinical data

Heart and Metabolism

Volumn , Issue 35, 2007, Pages

  Vergely, Catherine ^a   Delemasure, Stéphanie ^a   Cottin, Yves ^a,b   Rochette, Luc ^a  

^a IFR No 100   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

ACE inhibitors; Anthracyclines; Cardiotoxicity; Congestive heart failure; Reactive oxygen species

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTHRACYCLINE; ANTIOXIDANT; CATALASE; DAUNORUBICIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXORUBICIN; EPIRUBICIN; GLUTATHIONE; LYCOPENE; RAZOXANE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TIOPRONIN;

APOPTOSIS; CALCIUM HOMEOSTASIS; CANCER; CARDIOMYOPATHY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MEGADOSE; DRUG STRUCTURE; HEART PROTECTION; HUMAN; LEUKEMIA; LYMPHOMA; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REVIEW;

EID: 34548650592     PISSN: 15660338     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Dalloz F, Maingon P, Cottin Y, Briot F, Horiot JC, Rochette L. Effects of combined irradiation and doxorubicin treatment on cardiac function and antioxidant defenses in the rat. Free Radic Biol Med. 1999;26:785-800.
2. Berthiaume JM, Wallace KB. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol. 2007;23:15-25.
3. Puri A, Maulik SK, Ray R, Bhatnagar V. Electrocardiographic and biochemical evidence for the cardioprotective effect of vitamin E in doxorubicin-induced acute cardiotoxicity in rats. Eur J Pediatr Surg. 2005;15:387-391.
4. Venditti P, Balestrieri M, De Leo T, Di Meo S. Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc Res. 1998;38:695-702.
5. Yilmaz S, Atessahin A, Sahna E, Karahan I, Ozer S. Protective effect of lycopene on adriamycin-induced cardiotoxicity and nephrotoxicity. Toxicology. 2006;218:164-171.
6. Mohamed HE, El-Swefy SE, Hagar HH. The protective effect of glutathione administration on adriamycin-induced acute cardiac toxicity in rats. Pharmacol Res. 2000;42:115-121.
7. Villani F, Galimberti M, Zunino F, et al. Prevention of doxorubicin-induced cardiomyopathy by reduced glutathione. Cancer Chemother Pharmacol. 1991;28:365-369.
8. el-Missiry MA, Othman AI, Amer MA, Abd el-Aziz MA. Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats. Free Radic Res. 2001;35:575-581.
9. Chan EM, Thomas MJ, Bandy B, Tibbits GF. Effects of doxorubicin, 47′-epirubicin, and antioxidant enzymes on the contractility of isolated cardiomyocytes. Can J Physiol Pharmacol. 1996;74:904-910.
10. Konorev EA, Kennedy MC, Kalyanaraman B. Cell-permeable superoxide dismutase and glutathione peroxidase mimetics afford superior protection against doxorubicin-induced cardiotoxicity: the role of reactive oxygen and nitrogen intermediates. Arch Biochem Biophys. 1999;368:421-428.
11. Chaiswing L, Cole MP, Ittarat W, Szweda LI, St Clair DK, Oberley TD. Manganese superoxide dismutase and inducible nitric oxide synthase modify early oxidative events in acute adriamycin-induced mitochondrial toxicity. Mol Cancer Ther. 2005;4:1056-1064.
12. Kang YJ, Chen Y, Epstein PN. Suppression of doxorubicin cardiotoxicity by overexpression of catalase in the heart of transgenic mice. J Biol Chem. 1996;271:12610-12616.
13. Xiong Y, Liu X, Lee CP, Chua BH, Ho YS. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. Free Radic Biol Med. 2006;41:46-55.
14. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest. 1996;98:1253-1260.
15. Hasinoff BB, Schnabl KL, Marusak RA, Patel D, Huebner E. Dexrazoxane (ICRF-187) protects cardiac myocytes against doxorubicin by preventing damage to mitochondria. Cardiovasc Toxicol. 2003;3:89-99.
16. Cvetkovic RS, Scott LJ. Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy. Drugs. 2005;65:1005-1024.
17. Wouters KA, Kremer LC, Miller TL, Herman EH, Lipshultz SE. Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies. Br J Haematol. 2005;131:561-578.
18. Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol. 2006;33:S2-S7.
19. Van Dalen E, Van der Pal H, Caron H, Kremer L. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. The Cochrane Database of Systematic Reviews. The Cochrane Collaboration; issue 4. Oxford: Oxford Update Software, 2006: CD005008.
20. Delemasure S, Vergely C, Zeller M, Cottin Y, Rochette L. Preventing the cardiotoxic effects of anthracyclins. From basic concepts to clinical data [in French]. Ann Cardiol Angeiol (Paris). 2006;55:104-112.
21. Van Dalen E, Caron H, Dickinison H, Kremer L. Cardioprotective interventions for cancer patients receiving anthracylines. The Cochrane Database of Systematic Reviews. The Cochrane Collaboration; issue 1. Oxford: Oxford Update Software, 2006:CD003917.
22. Bryant J, Picot J, Baxter L, Levitt G, Sullivan I, Clegg A. Clinical and cost-effectiveness of cardioprotection against the toxic effects of anthracyclines given to children with cancer: a systematic review. Br J Cancer. 2007;96:226-230.
23. Yeh ET. Cardiotoxicity induced by chemotherapy and antibody therapy. Annu Rev Med. 2006;57:485-498.
24. Lambert C, Mossiat C, Tanniere-Zeller M, Maupoil V, Rochette L. Antiarrhythmic effect of amiodarone on doxorubicin acute toxicity in working rat hearts. Cardiovasc Res. 1990;24:653-658.
25. Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474-2481.